{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:50:11Z","timestamp":1793235011046,"version":"4.5.0"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2021,7,1]]},"DOI":"10.1001\/jamaneurol.2021.1272","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T11:35:55Z","timestamp":1621251355000},"page":"834","source":"Crossref","is-referenced-by-count":290,"title":["Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy"],"prefix":"10.1001","volume":"78","author":[{"given":"Jerry R.","family":"Mendell","sequence":"first","affiliation":[{"name":"Center for Gene Therapy, Nationwide Children\u2019s Hospital, Columbus, Ohio"},{"name":"Department of Pediatrics, The Ohio State University, Columbus"},{"name":"Department of Neurology, The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiah A.","family":"Al-Zaidy","sequence":"additional","affiliation":[{"name":"Al-Zaidy and Associates, LLC, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly J.","family":"Lehman","sequence":"additional","affiliation":[{"name":"Center for Gene Therapy, Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"McColly","sequence":"additional","affiliation":[{"name":"Center for Gene Therapy, Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda P.","family":"Lowes","sequence":"additional","affiliation":[{"name":"Center for Gene Therapy, Nationwide Children\u2019s Hospital, Columbus, Ohio"},{"name":"Department of Pediatrics, The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay N.","family":"Alfano","sequence":"additional","affiliation":[{"name":"Center for Gene Therapy, Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie F.","family":"Reash","sequence":"additional","affiliation":[{"name":"Center for Gene Therapy, Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan A.","family":"Iammarino","sequence":"additional","affiliation":[{"name":"Center for Gene Therapy, Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen R.","family":"Church","sequence":"additional","affiliation":[{"name":"Center for Gene Therapy, Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Kleyn","sequence":"additional","affiliation":[{"name":"Novartis Gene Therapies, Inc, Bannockburn, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew N.","family":"Meriggioli","sequence":"additional","affiliation":[{"name":"Novartis Gene Therapies, Inc, Bannockburn, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Shell","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Ohio State University, Columbus"},{"name":"Section of Pulmonary Medicine, Department of Pediatrics, Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"noi210023r1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens.","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"noi210023r2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014a literature review.","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"noi210023r3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/JND-180304","article-title":"Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening.","volume":"5","author":"Glascock","year":"2018","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"noi210023r4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care.","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"noi210023r5","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials.","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"noi210023r6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.v82.6","article-title":"Natural history of infantile-onset spinal muscular atrophy.","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann Neurol"},{"issue":"15","key":"noi210023r7","doi-asserted-by":"publisher","first-page":"e1634","DOI":"10.1212\/WNL.0000000000009248","article-title":"Population-based analysis of survival in spinal muscular atrophy.","volume":"94","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"issue":"3","key":"noi210023r9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN.","volume":"28","author":"Foust","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"18","key":"noi210023r10","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy.","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"noi210023r12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.","author":"Chand","year":"2021","journal-title":"J Hepatol"},{"key":"noi210023r13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series.","author":"Chand","year":"2021","journal-title":"J Pediatr"},{"issue":"20","key":"noi210023r14","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"noi210023r15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","article-title":"Impact of age and motor function in a phase 1\/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy.","volume":"98","author":"Lowes","year":"2019","journal-title":"Pediatr Neurol"},{"issue":"5","key":"noi210023r16","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/(ISSN)1531-8249","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function.","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann Neurol"},{"issue":"3","key":"noi210023r17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ana.v81.3","article-title":"Emerging therapies and challenges in spinal muscular atrophy.","volume":"81","author":"Farrar","year":"2017","journal-title":"Ann Neurol"},{"issue":"11","key":"noi210023r18","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study.","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"noi210023r19","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.25135","article-title":"The respiratory impact of novel therapies for spinal muscular atrophy.","author":"Paul","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"noi210023r20","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.","author":"Day","journal-title":"Lancet Neurol"},{"issue":"10250","key":"noi210023r25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0140-6736(20)31787-6","article-title":"COVID-19 and readjusting clinical trials.","volume":"396","author":"van Dorn","year":"2020","journal-title":"Lancet"},{"key":"noi210023r8","unstructured":"AveXis, Inc. ZOLGENSMA\u00ae (onasemnogene abeparvovec-xioi). 2021. Accessed April 13, 2021. https:\/\/www.fda.gov\/media\/126109\/download"},{"key":"noi210023r11","unstructured":"Gene transfer clinical trial for spinal muscular atrophy type 1. ClinicalTrials.gov identifer: NCT02122952. Updated May 10, 2019. Accessed April 8, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02122952"},{"key":"noi210023r21","unstructured":"Single-dose gene replacement therapy clinical trial for participants with spinal muscular atrophy type 1 (STRIVE-EU). ClinicalTrials.gov identifier: NCT03461289. Updated April 2, 2021. Accessed April 15, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03461289"},{"key":"noi210023r22","unstructured":"Single-dose gene replacement therapy using for patients with spinal muscular atrophy type 1 with one or two SMN2 copies. ClinicalTrials.gov identifier: NCT03837184. Updated March 30, 2021. Accessed April 8, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03837184"},{"key":"noi210023r23","unstructured":"Pre-symptomatic study of intravenous onasemnogene abeparvovec-xioi in spinal muscular atrophy (SMA) for patients with multiple copies of SMN2 (SPR1NT). ClinicalTrials.gov identifier: NCT03505099. Updated March 30, 2021. Accessed April 8, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03505099"},{"key":"noi210023r24","unstructured":"Long-term follow-up study of patients receiving onasemnogene abeparvovec-xioi. ClinicalTrials.gov identifier: NCT04042025. Updated March 30, 2021. Accessed April 8, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04042025"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2780250\/jamaneurology_mendell_2021_oi_210023_1624467431.00495.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T19:56:16Z","timestamp":1625774176000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2780250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2021.1272","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,1]]}}}